RT Journal Article SR Electronic T1 The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer JF International Journal of Gynecologic Cancer JO Int J Gynecol Cancer FD BMJ Publishing Group Ltd SP 641 OP 655 DO 10.1097/IGC.0000000000001216 VO 28 IS 4 A1 David Cibula A1 Richard Pötter A1 François Planchamp A1 Elisabeth Avall-Lundqvist A1 Daniela Fischerova A1 Christine Haie Meder A1 Christhardt Köhler A1 Fabio Landoni A1 Sigurd Lax A1 Jacob Christian Lindegaard A1 Umesh Mahantshetty A1 Patrice Mathevet A1 W. Glenn McCluggage A1 Mary McCormack A1 Raj Naik A1 Remi Nout A1 Sandro Pignata A1 Jordi Ponce A1 Denis Querleu A1 Francesco Raspagliesi A1 Alexandros Rodolakis A1 Karl Tamussino A1 Pauline Wimberger A1 Maria Rosaria Raspollini YR 2018 UL http://ijgc.bmj.com/content/28/4/641.abstract AB Background Despite significant advances in the screening, detection, and treatment of preinvasive cervical lesions, invasive cervical cancer is the fifth most common cancer in European women. There are large disparities in Europe and worldwide in the incidence, management, and mortality of cervical cancer.Objective The European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) jointly develop clinically relevant and evidence-based guidelines in order to improve the quality of care for women with cervical cancer across Europe and worldwide.Methods The ESGO/ESTRO/ESP nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of cervical cancer (23 experts across Europe). To ensure that the guidelines are evidence based, the current literature identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 159 international reviewers, selected through ESGO/ESTRO/ESP and including patient representatives.Results The guidelines cover comprehensively staging, management, and follow-up for patients with cervical cancer. Management includes fertility sparing treatment; stage T1a, T1b1/T2a1, clinically occult cervical cancer diagnosed after simple hysterectomy; early and locally advanced cervical cancer; primary distant metastatic disease; cervical cancer in pregnancy; and recurrent disease. Principles of radiotherapy and pathological evaluation are defined.